Groupe Francophone Des Myelodysplasies
Clinical trials sponsored by Groupe Francophone Des Myelodysplasies, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New combo tackles relapsed blood cancers after transplant Results expected Nov 2026 (estimated)
- Can a Gene-Targeted pill turn the tide against a rare blood cancer? Results expected Apr 2027 (estimated)
-
New drug hope for rare inflammatory VEXAS syndrome
Disease control Recruiting nowThis phase 2 trial tests the drug momelotinib in 57 people with VEXAS syndrome, a rare inflammatory condition that may also involve a bone marrow disorder called MDS. Participants receive momelotinib daily, and doctors check if symptoms improve and if steroid doses can be lowered…
Phase 2 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Could a Centuries-Old poison become a new weapon against a blood disorder?
Disease control Recruiting nowThis early-stage trial is testing whether an oral form of arsenic trioxide can safely help people with low-risk myelodysplastic syndromes (MDS) who have not improved with standard treatments. The study will first find the safest dose, then check how well it works after several cy…
Phase 1 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New combo therapy aims to boost red blood cells in MDS patients
Disease control Recruiting nowThis study tests a combination of two drugs—luspatercept and erythropoietin (EPO)—for people with a low-risk form of myelodysplastic syndrome (MDS) that does not involve ring sideroblasts. Participants must have already tried EPO alone without success or be unable to take it. The…
Phase 1/2 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC